Background: Gastric cancer is a complex disease and the third leading cause of cancer deaths worldwide. To date, surgery remains the only curative strategy in locally advanced gastric cancer (LAGC) patients (pt), although the results of the MAGIC trial supported the implementation of a perioperative treatment (ttx) with epirubicincisplatin-5FU (ECF). Since 2019, the FLOT4-AIO trial showed that perioperative 5FUleucovorin-oxaliplatin-docetaxel (FLOT) improved median overall survival (mOS) compared to ECF. We aimed to assess outcome differences in a non-clinical trial scenario in our LAGC cohort, according to multidisciplinary management in a highly specialized gastro-esophageal cancer functional unit (UFEG) integrating different specialists.Methods: From 2012 to 2018, 114 newly diagnosed LAGC pt were referred to our UFEG. Several UFEG specialists at this first consultation evaluated every case, in order to establish a multimodal therapeutic plan. UFEG is comprised of digestive surgeons, medical oncologists, radiation oncologists, nutritionists, advanced practice nurses, radiologists, digestive endoscopists, pathologists, supportive care physicians, and social workers. All demographic, treatment and survival data were extracted retrospectively from available electronic medical records. abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S193
O câncer de mama é umas das principais causas de morte de mulheres no mundo, no Brasil a realidade não é diferente. Identificar fatores de riscos e analisar o efeito dos tratamentos na vida dos pacientes são de extrema importância para o melhor entendimento dessa doença. Este trabalho tem como objetivo analisar a proporção de mulheres que sobrevivem por um longo período de tempo após serem diagnosticadas com câncer de mama. Para isso se faz uso de modelos estatísticos que permitem acomodar tais características. Os dados analisados são de pacientes que foram diagnosticadas com câncer de mama triplo negativo e submetidas ao tratamento quimioterápico no A.C.Camargo Câncer Center. Alguns fatores que influenciam na determinação da proporção de cura são identificados. Nota-se que mulheres que apresentam inicialmente um melhor prognóstico mostram uma maior chance de sobreviver por um longo período de tempo, indicando assim a necessidade de ampliação do rastreamento e diagnóstico precoce do câncer de mama.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.